Clinical trial
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic…
NCT00398112 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00398112 |
|---|---|
| Title | Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| Official title | A Phase II Study of Sunitinib Malate for Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia |
| Intervention type | Drug, Other |
| Interventions | sunitinib malate, pharmacological study, laboratory biomarker analysis |
| Enrollment | 18 |
| Start date | Aug 1, 2007 |
| Primary completion | Nov 1, 2008 |
| Completion | Jan 1, 2011 |
| First posted | Nov 10, 2006 |
| Last update posted | May 14, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: